<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="560">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>5/10/2005</approvaldate>
  <actrnumber>ACTRN12605000590662</actrnumber>
  <trial_identification>
    <studytitle>Phase III trial of an immunotherapy for Stage III (AJCC) melanoma based on  cultured autologous dendritic cells presenting autologous tumour cell  antigens</studytitle>
    <scientifictitle>Phase III trial of an immunotherapy for Stage III (AJCC) melanoma based on  cultured autologous dendritic cells presenting autologous tumour cell  antigens to test the effect on distant disease-free survival at 2 years, time to distant, or untreatable local recurrence and safety.</scientifictitle>
    <utrn />
    <trialacronym>MRPQ0161(A)</trialacronym>
    <secondaryid>Queensland Institute of Medical Research (QIMR): QIMR P742</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Stage III B/C (AJCC) Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention: autologous dendritic cell vaccine using autologous irradiated tumor cells as antigen source;
Duration of intervention: two years or until disease recurrence.</interventions>
    <comparator>
Control: autologous peripheral mononuclear blood cells</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Distant disease-free survival at 2 years</outcome>
      <timepoint>Safety assessments as clinically indicated and at each vaccination visit (fortnightly for a max of 8 weeks, then every 3 months) for first two years, then 6 monthly for 12 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to distant, or untreatable local recurrence</outcome>
      <timepoint>Safety assessments as clinically indicated and at each vaccination visit (fortnightly for a max of 8 weeks, then every 3 months) for first two years, then 6 monthly for 12 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>As information becomes available and at the end of the follow up period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in in vivo and in vitro immunological responsiveness to autologous melanoma at each vaccination.</outcome>
      <timepoint>fortnightly for up to 8 weeks, then 3 monthly for up to 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically confirmed melanoma of Stage III; ECOG status 0; Normal Haematolology; Acceptable Renal and Liver function parameters; Negative serology for HIV, Hep B and C;Informed written consent.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Autoimmune disease or immunosuppressant use, Prior chemotherapy,  immunotherapy, gene therapy, vaccine therapy,  cytokine therapy, post-operative complications which would preclude experimental vaccine therapy, Unsuccessful vaccine preparation, Clinically significant active infection, Uncontrolled systemic disease or medical problems, History of other malignancies (except for adequately treated and controlled non-melanomatic skin cancer or in situ cervical cancer), Pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Double blind, fixed allocation, sequential, centrally assigned randomisation, performed by QA administration using a list concealed from clinical investigators</concealment>
    <sequence>Block design, fixed allocation randomization based on stratification variables. Sequence generated using SAS.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>22/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Queensland Institute of Medical Research (QIMR)</primarysponsorname>
    <primarysponsoraddress>300 Herston Rd, Herston, Queensland 4006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Atlantic Philanthropies</fundingname>
      <fundingaddress>49 Albermarle St London WIS 4JR</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Queensland Cancer Fund</fundingname>
      <fundingaddress>550 Gregory Terrace, Fortitude Valley, Brisbane</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>QIMR</ethicname>
      <ethicaddress>Herston, QLD 4029</ethicaddress>
      <ethicapprovaldate>6/02/2004</ethicapprovaldate>
      <hrec>EC00278</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress>Woolloongabba, QLD 4102</ethicaddress>
      <ethicapprovaldate>20/01/2004</ethicapprovaldate>
      <hrec>EC00332</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Misericordiae Hospital</ethicname>
      <ethicaddress>South Brisbane, QLD 4101</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Chris Schmidt</name>
      <address>Queensland Institute of Medical Research 300 Herston Road
Herston QLD 4006</address>
      <phone>+61 7 33620313</phone>
      <fax>+61 7 38453510</fax>
      <email>Chris.Schmidt@qimr.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Maree Johnson</name>
      <address>Department of Surgery
Mater Adult Hospital
Brisbane QLD 4012</address>
      <phone>+61 7 38401696</phone>
      <fax>+61 7 38401696</fax>
      <email>2surah@mater.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Agnieszka Mitchell</name>
      <address>Queensland Institute of Medical Research
300 Herston Rd Brisbane 4006</address>
      <phone>(07) 3362 0241</phone>
      <fax>(07) 3362 0109</fax>
      <email>agnieszka.mitchell@qimr.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>